Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATACC: p53-Specific T Cells in Advanced Colorectal Cancer
NCT02577588Phase 1Terminated
- Sponsor
- National Center for Tumor Diseases
- Start
- May 2016
- Primary completion
- Feb 2018
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous p53-specific T cells in colorectal cancer (CRC), sponsored by National Center for Tumor Diseases. Primary endpoint: Safety and tolerability at 45 days. Started May 2016; status: terminated.
02
Drugs
autologous p53-specific T cells
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02577588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02577588.